This international, peer-reviewed Open Access journal by Dove Medical Press focuses on pathophysiological processes underlying Chronic Obstructive Pulmonary Disease (COPD) interventions, patient focused education, and self-management protocols. Sign up for email alerts here.
39,063 Monthly downloads/views I 2.893 Impact Factor I 5.2 CiteScore I 1.16 Source Normalized Impact per Paper (SNIP) I 0.804 Scimago Journal & Country Rank (SJR)
Record: found
Abstract: found
Article: found
Is Open Access
Acute Effects of Air Pollution on Hospital Admissions for Asthma, COPD, and Bronchiectasis in Ahvaz, Iran
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Background and Aim
Although air pollution is a serious problem in Ahvaz, the association between air
pollution and respiratory diseases has not been studied enough in this area. The aim
of this study was to determine the relation between short-term exposure to air pollutants
and the risk of hospital admissions due to asthma, COPD, and bronchiectasis in Ahvaz.
Methods
Hospital admissions data and air pollutants including O
3, NO, NO
2, SO
2, CO, PM
10, and PM
2.5 were obtained from 2008 to 2018. Adjusted Quasi-Poisson regression with a distributed
lag model, controlled for trend, seasonality, weather, weekdays, and holidays was
used for data analysis.
Results
The results showed a significant increase in hospital admissions for asthma (RR=1.004,
95% CI: 1.002–1.007) and COPD (RR=1.003, 95% CI: 1.001–1.005) associated with PM
2.5. PM
10 was associated with increased hospital admissions due to bronchiectasis in both genders
(Men: RR=1.003, 95% CI: 1.001–1.006) (Female: RR=1.003, 95% CI: 1.000–1.006). NO
2 was also associated with an increased risk of hospital admissions for asthma (RR=1.040,
95% CI: 1.008–1.074) and COPD (RR=1.049, 95% CI: 1.010–1.090). SO
2 was associated with the risk of hospital admissions of asthma (RR=1.069, 95% CI:
1.017–1.124) and bronchiectasis (RR=1.030, 95% CI: 1.005–1.056). Finally, CO was associated
with COPD (RR=1.643, 95% CI: 1.233–2.191) and bronchiectasis (RR=1.542, 95% CI: 1.035–2.298)
hospital admissions.
Conclusion
Short-term exposure to air pollutants significantly increases the risk of hospital
admissions for asthma, COPD, and bronchiectasis in the adult and elderly population.
Chronic respiratory diseases receive little attention and funding in comparison with other major causes of global morbidity and mortality [1]. Chronic obstructive pulmonary disease (COPD) is a major public health problem. COPD is the end result of a susceptible lung being exposed to sufficient environmental stimulus. Caused principally by tobacco smoking and household air pollution (HAP), COPD is a silent killer in low- and middle-income countries (LMICs): an estimated 328 million people have COPD worldwide [2], and in 15 years, COPD is expected to become the leading cause of death [3]. The relentless decline in lung function that characterises COPD is associated with progressive symptoms and functional impairment, with susceptibility to respiratory infections called ‘exacerbations’. Exacerbations are responsible for much of the morbidity and mortality. COPD has a significant impact on quality of life for those living with the condition, and on local economies for those affected, those caring for the affected and health services. A population literally struggling for breath is, in consequence, unproductive. The majority of cases of chronic lung disease are preventable. Exposure reduction initiatives must focus on tobacco control, and cook-stove interventions: either cleaner fuel (ideally), or better ventilation (at the least). Awareness campaigns and health programmes have the potential to revolutionise the diagnosis and management of COPD and COPD exacerbations, improving quality of life and health service cost and burden. LMICs face unique challenges in managing COPD, including sub-optimal and diverse primary care systems which present challenges with diagnosis and management, especially during exacerbations. A better understanding of how to prevent, diagnose and manage COPD in both rural and urban settings would make a real difference in countries of need. Two important aspects to consider when addressing the global economic burden of COPD are that of underdiagnosis and comorbidities [4]. Firstly, COPD remains underdiagnosed in many jurisdictions [5]. Studies included in reviews focusing on the global economic burden of COPD are all based on diagnosed COPD, and a simple multiplication of these values by the number of COPD patients to calculate the overall economic burden of COPD will underestimate the contribution of undiagnosed COPD [5]. Secondly, COPD is known to be associated with a significant number of comorbid conditions, and estimating costs that are directly attributable to COPD fails to consider the burden of such comorbidities [4]. Adjusting for comorbidities by calculating excess costs with an appropriate comparison group can provide a better opportunity, but even this results in an underestimation of the costs of the comorbidities [6–8]. Global COPD statistics More than 90% of COPD-related deaths occur in LMICs [3]. According to the Global Burden of Disease (GBD), COPD is already the third leading cause of death worldwide, something that WHO had not predicted to occur until 2030 [9]. The economic impact of COPD among LMICs is expected to increase to £1.7 trillion by 2030 [10]. In 15 years, COPD is expected to become the leading cause of death worldwide [3]. Air pollution and HAP Air pollution is the biggest environmental cause of death worldwide, with HAP accounting for about 3.5–4 million deaths every year [11]. Extensive literature supports a causal association between HAP and chronic lung diseases [12], respiratory infections and respiratory tract cancers. One-third of the world's population, some three billion people use fuel derived from organic material (biomass) or solid fuel including coal, wood and charcoal as an energy source to heat and light their homes, and to cook. Respiratory morbidity relates to products of incomplete combustion such as carbon monoxide, and to particulate matter (PM). PM include both organic and inorganic particles, and represents the sum of all solid and liquid particles suspended in the air, many of which are hazardous. PM10 is the most widely used indicator of the health hazard of indoor air pollution. The EU and the US Environmental Protection Agency have set standards for annual mean PM10 levels in outdoor air at 40 and 50 µg/m3, respectively [13]. When burning solid fuels, peak levels of PM10 in biomass-using homes can be as high as 10 000 µg/m3, 200 times more than the standard in high-income countries. PM2.5 are finer particles which penetrate deep into the lung and have the greatest health-damaging potential. Pollutants are particularly damaging and of concern to children growing up in homes with HAP, the effect on the developing lung results in lung function that does not reach maximum potential. Household air pollution statistics Air pollution is the biggest environmental cause of death worldwide [14]. Three billion people worldwide are exposed to toxic amounts of HAP every day [11]. HAP accounts for up to four million deaths annually [11]. Smoking Tobacco is a legal drug which is currently responsible for the deaths of an estimated six million people across the world each year, with many of these deaths occurring prematurely [15]. Tobacco smoking is associated with morbidity and mortality from non-communicable respiratory diseases (NCDs), including about 600 000 people who are estimated to die every year from the effects of second-hand smoke [15]. The poor tend to smoke the most. Globally, 84% of smokers live in developing and transitional economy countries [16]. Tobacco smoke potentiates the detrimental effects of biomass smoke exposure. The WHO stated that in 2015, over 1.1 billion people smoked tobacco, males smoked tobacco more than females, and although it is declining worldwide and in many countries, the prevalence of tobacco smoking appears to be increasing in the Eastern Mediterranean and Africa [17]. Tobacco and smoking statistics Due to the incomplete combustion of formaldehyde and DEET, one mosquito coil burning for 8 h releases the same amount of PM2.5 as 100 cigarettes [18]. A 1 h hookah session with shisha tobacco is equivalent to smoking over 100 cigarettes [19]. Those who have never smoked tobacco can still get COPD – think ‘biomass COPD’. COPD: under-recognition and inequity There is a need for governments, policy makers and international organizations to consider strengthening collaborations to address COPD. TB, HIV/AIDS and malaria all compete for headlines and funds; COPD is rarely the headline. There is global under-recognition of COPD. This needs to change and we welcome recent initiatives highlighting unmet needs in NCDs. The United Nations (UN) declaration of NCDs, and the World Health Assembly in 2012, endorsed a new health goal (the ‘25 by 25 goal’), which focuses on the reduction of premature deaths from COPD and other NCDs by 25% by the year 2025 [20]. Many NCDs occur together in the context of multi-morbidity, yet despite this initiative, COPD remains a growing but neglected global epidemic. It is under-recognised, under-diagnosed and under-treated resulting in millions of people continuing to suffer from this preventable and treatable condition. The lower an individual's socio-economic position, the higher their risk of poor health: women and children living in severe poverty have the greatest exposures to HAP [21]. In the poorest countries, cooking with solid fuels can be the equivalent of smoking two packs of cigarettes a day [22]. A 1-year old would have accumulated a two pack year smoking history having never seen tobacco. Inaction to mitigate COPD therefore exacerbates health inequalities. Climbing the ‘energy ladder’ occurs gradually as most LMIC households use a combination of fuels. The poorest, at the bottom of the ladder, use crop waste or dung which is the most harmful when undergoing incomplete combustion. Those at the top of the ladder use electricity or natural gas. Increasing prosperity and development has a direct positive correlation with increasing use of cleaner and more efficient fuels for cooking [23]. The unmet global burden of COPD is a silent killer in LMICs. In conclusion, we suggest that given the high and rising global burden of COPD, a revolution in the diagnosis and management of COPD and exacerbations of COPD in LMICs must be an urgent priority. Summary An estimated 328 million people have COPD worldwide [3]. In 15 years, COPD is expected to become the leading cause of death worldwide [3]. Three billion people worldwide are exposed to toxic amounts of HAP every day and HAP accounts for 3.5–4 million deaths annually [11]. Those who have never smoked tobacco can still get COPD – think ‘biomass COPD’.
Ambient air pollution (AAP) and particulate matters (PM) have been closely associated with adverse health effects such as respiratory disease and cardiovascular diseases. Previous studies have examined the adverse health effects associated with short- and long-term exposure to AAP and outdoor PM on respiratory disease. However, the effect of PM size (PM2.5 and PM10) on cardiovascular disease has not been well studied. Thus, it remains unclear how the size of the inhalable particles (coarse, fine, or ultrafine) affects mortality and morbidity. Airborne PM concentrations are commonly used for ambient air quality management worldwide, owing to the known effects on cardiorespiratory health. In this article, we assess the relationship between cardiovascular diseases and PM, with a particular focus on PM size. We discuss the association of PM2.5 and PM10, nitrogen dioxide (NO2), and elemental carbon with mortality and morbidity due to cardiovascular diseases, stroke, and altered blood pressure, based on epidemiological studies. In addition, we provide evidence that the adverse health effects of AAP and PM are more pronounced among the elderly, children, and people with preexisting cardiovascular and respiratory conditions. Finally, we critically summarize the literature pertaining to cardiovascular diseases, including atherosclerosis and stroke, and introduce potential studies to better understand the health significance of AAP and PM on cardiovascular disease.
Journal ID (nlm-ta): Int J Chron Obstruct Pulmon Dis
Journal ID (iso-abbrev): Int J Chron Obstruct Pulmon Dis
Journal ID (publisher-id): COPD
Journal ID (pmc): copd
Title:
International Journal of Chronic Obstructive Pulmonary Disease
Publisher:
Dove
ISSN
(Print):
1176-9106
ISSN
(Electronic):
1178-2005
Publication date
(Electronic):
03
March
2020
Publication date Collection: 2020
Volume: 15
Pages: 501-514
Affiliations
[1
]Department of Internal Medicine, Air Pollution and Respiratory Diseases Research Center,
Ahvaz Jundishapur University of Medical Sciences , Ahvaz, Iran
[2
]Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University
of Medical Sciences , Ahvaz, Iran
[3
]Department of Emergency Medicine, Air Pollution and Respiratory Diseases Research
Center, Ahvaz Jundishapur University of Medical Sciences , Ahvaz, Iran
[4
]Environmental Health Engineering Research Center, Kerman University of Medical Sciences , Kerman, Iran
[5
]Department of Biostatistics and Epidemiology, Air Pollution and Respiratory Diseases
Research Center, Ahvaz Jundishapur University of Medical Sciences , Ahvaz, Iran
[6
]Department of Environmental Health Engineering, Air Pollution and Respiratory Diseases
Research Center, Ahvaz Jundishapur University of Medical Sciences , Ahvaz, Iran
Author notes
Correspondence: Maryam Dastoorpoor Department of Biostatistics and Epidemiology, Air
Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of
Medical Sciences , Ahvaz, Iran Tel +98 61 333 6754 Email mdastoorpour@yahoo.com
This work is published and licensed by Dove Medical Press Limited. The full terms
of this license are available at
https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0)
License (
http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work
are permitted without any further permission from Dove Medical Press Limited, provided
the work is properly attributed. For permission for commercial use of this work, please
see paragraphs 4.2 and 5 of our Terms (
https://www.dovepress.com/terms.php).
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.